Use of Biologic Treatment for Cutaneous Behcet’s Disease: An Evidence-Based Review

Abstract

Keywords

Behcet’s disease biologic agents biologic treatment mucocutaneous lesions systematic review treatment outcomes adalimumab ustekinumab

Get full access to this article

View all access options for this article.

References

Alibaz-Oner

Direskeneli

. Advances in the treatment of Behcet’s disease. Curr Rheumatol Rep. 2021;23(6):47. doi:10.1007/s11926-021-01011-z

Saleh

Arayssi

. Update on the therapy of Behçet disease. Ther Adv Chronic Dis. 2014;5(3):112-134. doi:10.1177/2040622314523062

Tong

Liu

Xiao

. Immunopathogenesis of Behcet’s disease. Front Immunol. 2019;10:665. doi:10.3389/fimmu.2019.00665

Kim

Nakamura

Kaneko

Alpsoy

Bang

. Mucocutaneous manifestations of Behçet’s disease: pathogenesis and management from perspectives of vasculitis. Front Med (Lausanne). 2022;9:987393. doi:10.3389/fmed.2022.987393

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB

0.03 MB

0.05 MB

0.02 MB